Compare QUALCOMM, Inc. (QCOM) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
QUALCOMM, Inc. vs Travere Therapeutics Inc. Common Stock — how do they compare? QUALCOMM, Inc. trades at $170.88 (market cap $188.86B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: QUALCOMM, Inc. is far larger — about 38.7× Travere Therapeutics Inc. Common Stock's market cap, and QUALCOMM, Inc. pays a 2.08% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold QUALCOMM, Inc. for 87 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| QCOM | TVTX | |
|---|---|---|
Market Cap | $188.86B | $4.88B |
Volume | 12,280,716 | 1,668,577 |
Sector | Technology | Health |
52-Week High | $251.10 | $67.52 |
52-Week Low | $124.07 | $26.79 |
Typical Hold Time | 87 Days | 0 Days |
Enterprise Value | $195.82B | $5.01B |
Dividend Yield | 2.08% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Qualcomm (QCOM) trades at $174.43, down 0.61% today, with a bearish technical signal despite recent AI-driven optimism. The company reported mixed Q2 2026 earnings, missing EPS estimates at $2.21 versus $2.23 expected, but maintains strong profitability with 54.23% gross margins and 21.01% net income margin. Recent news highlights a transformative $60 billion Amazon AI partnership, boosting data center ambitions beyond its core handset business.
QCOM's valuation appears reasonable with a P/E of 20.21, trading below the analyst consensus price target of $204.48. Key opportunities include AI data center growth and automotive expansion, while risks involve smartphone dependency and competitive pressures. Wall Street sentiment is mixed with 43.48% buy ratings, but the stock offers potential upside if AI bets materialize.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About QUALCOMM, Inc.
Qualcomm develops and licenses wireless technology and designs chips for smartphones. The company's key patents revolve around CDMA and OFDMA technologies, which are standards in wireless communications that are the backbone of all 3G and 4G networks. The firm is a leader in 5G network technology as well. Qualcomm's IP is licensed by virtually all wireless device makers. The firm is also the world's largest wireless chip vendor, supplying nearly every premier handset maker with leading-edge processors. Qualcomm also sells RF-front end modules into smartphones and chips into automotive and Internet of Things markets.
Read more on QCOM →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
